Canadian Diabetes Association announces Elsevier as new publisher of Canadian Journal of Diabetes

November 18, 2011

Toronto, November 17, 2011 - The Canadian Diabetes Association is pleased to announce that it has entered into an agreement with Elsevier to publish the Canadian Journal of Diabetes (CJD) beginning in January 2012.

CJD is Canada's only diabetes-oriented, peer-reviewed, interdisciplinary journal for diabetes healthcare professionals and scientists. It promotes the sharing and enhancement of knowledge to advance the prevention, cure and management of diabetes and related diseases. The journal publishes original research articles and expert reviews, ranging from basic sciences to clinical applications, education, public and population health, and health policy.

"We are very pleased to be partnering with Elsevier," said Michael Cloutier, President and CEO, Canadian Diabetes Association. "They are an innovative and leading publisher in medical information and, together, we will bring the Canadian Journal of Diabetes to new heights of excellence."

Andrew Miller, Executive Publisher, Global Medical Research, Elsevier stated, "We are very proud to be chosen as publisher for Canadian Journal of Diabetes. We look forward to further developing CJD in partnership with the Canadian Diabetes Association for the diabetes research and clinical-care communities."

Under the agreement with Elsevier, the Association will still own the journal, maintain copyright, and retain full editorial control. Elsevier will manage CJD publication, website features, print and online subscriptions, advertising, and marketing.

The decision to partner with Elsevier was reached by the Association after a long and thorough review process. The advantages of Elsevier's global reach and experience in the ever-changing field of scientific publication will not only benefit the CJD and its authors, but its readers as well.
-end-
About the Canadian Diabetes Association

Across the country, the Canadian Diabetes Association is leading the fight against diabetes by helping people with diabetes live healthy lives while we work to find a cure. Our community-based network of supporters help us provide education and services to people living with diabetes, advocate for our cause, break ground towards a cure and translate research into practical applications. Visit http://www.diabetes.ca; http://www.facebook.com/CanadianDiabetesAssociation; on Twitter @DiabetesAssoc; call 800-BANTING (226-8464).

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contacts

Randi Garcha
Canadian Diabetes Association
Manager, National Media Relations & External Communications
416-408-7071
randi.garcha@diabetes.ca

Andrew Miller
Executive Publisher, Global Medical Research Elsevier
44-1865-843823
andrew.miller@elsevier.com

Elsevier

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.